Trials / Completed
CompletedNCT00988312
Dendritic Cells(DC)-Based Id Vaccination in Stage-I Myeloma
Vaccination With Idiotype-KLH Loaded Dendritic Cells. A Phase I Study for Patients With Multiple Myeloma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- University Hospital Carl Gustav Carus · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Patients with stage-I multiple myeloma are treated with a vaccine made from their own immune cells (dendritic cells) and their own myeloma protein. Vaccinations are given on 5 occasions every 4 weeks. The aim is to induce an immune reaction against the malignant myeloma cells in order to slow down or cure the disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | autologous idiotype-protein pulsed dendritic cells | Vaccination with autologous idiotype-protein pulsed dendritic cells on 5 occasions every 4 weeks |
Timeline
- Start date
- 2002-03-01
- Primary completion
- 2004-02-01
- Completion
- 2004-03-01
- First posted
- 2009-10-02
- Last updated
- 2009-10-02
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00988312. Inclusion in this directory is not an endorsement.